Home 3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
 

Keywords :   


3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year

2015-03-01 17:35:43| Biotech - Topix.net

Revlimid was already on pace to deliver sales of more than $5 billion this year as the leading second-line treatment for the indication; the FDA and EU's approval for its use in newly diagnosed patients could mean that sales finish 2015 closer to an annualized $6 billion pace than a $5 billion pace. Celgene should also be able to notch solid sales growth from its third-line multiple myeloma drug Pomalyst and its cancer drug Abraxane.

Tags: this year big sciences

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.11Subtropical Storm Patty Graphics
02.11Subtropical Storm Patty Forecast Discussion Number 1
02.11Subtropical Storm Patty Wind Speed Probabilities Number 1
02.11Subtropical Storm Patty Forecast Advisory Number 1
02.11Subtropical Storm Patty Public Advisory Number 1
02.11Summary for Subtropical Storm Patty (AT2/AL172024)
02.11Tropical Storm Lane Graphics
02.11Tropical Storm Lane Forecast Discussion Number 3
More »